Edinburgh, UK, 5th December 2018 / Synpromics is pleased to hear that its partner, uniQure (NASDAQ:QURE), has announced the incorporation of its promoter, develope
Edinburgh, UK, 16th November 2018 / Synpromics, the leader in gene control, is delighted to announce that it has been ranked 12th in the
A new video from Synpromics’ investor, Calculus Capital, discusses why they invest and how this has aided development of our synthetic promoter technology.
Sarah Haecker Meeks and David Venables enjoyed the sun in San Diego earlier this month for the annual ARM Cell & Gene Meeting on the Mesa.
Edinburgh, 18th October, 2018 / Synpromics is pleased to announce positive data presented today by a key partner, uniQure (NASDAQ:QURE), at the European